Congratulations to Tope on a Drug Resistance Updates Review of Peptidomimetics

Cover of Drug Resistance Updates

The Kumar Research Group is delighted to congratulate Tope A. Ibisanmi and all co-authors on a new review now available online in Drug Resistance Updates.

Advancements in Peptidomimetics as a Strategy Against Multidrug Resistance: Fundamentals, Rational Design, Resistance Mechanisms, and Artificial Intelligence brings together the chemistry, biology, and emerging computational approaches in this area. Antimicrobial resistance continues to challenge effective treatment, and new approaches to antibacterial discovery are urgently needed.

The review discusses major peptidomimetic scaffold classes, how their properties shape antibacterial activity, how resistance mechanisms such as membrane remodelling may undermine them, and where molecular modelling and artificial intelligence could contribute. A central contribution is an integrated developability framework. It asks whether a peptidomimetic’s potency holds under physiological conditions, remains robust against bacterial adaptation, and can meet translational constraints. For each scaffold, the framework asks what mechanism it exploits, which resistance liability may threaten it, and what clinical indication its properties could realistically support.

Publication details:

  • Journal: Drug Resistance Updates (2026), Article 101490
  • Title: Advancements in peptidomimetics as a strategy against multidrug resistance: Fundamentals, rational design, resistance mechanisms, and artificial intelligence
  • Authors: Tope Abraham Ibisanmi, Ghayah Bahatheg, Umme Laila Urmi, Shyam Kumar Mishra, Rasel Ahmed Khan, Jiawei Shen, George Nkrumah Enninful, Tuong Anh To, Mark D. P. Willcox, and Naresh Kumar
  • DOI: 10.1016/j.drup.2026.101490
  • Read the paper: ScienceDirect
  • Announcement: Professor Naresh Kumar on LinkedIn

Congratulations to Tope and all co-authors. Special thanks to Professor Naresh Kumar and Professor Mark Willcox for the guidance and support that made this work possible. The Kumar Research Group is proud of this contribution to antimicrobial drug discovery.